维奈克拉联合克拉屈滨及低剂量阿糖胞苷与5-阿扎胞苷交替方案治疗老年新诊断急性髓系白血病的II期研究
这项II期研究纳入60例老年(≥60岁)或不适合强化疗的新诊断急性髓系白血病患者,采用维奈克拉联合克拉屈滨/低剂量阿糖胞苷与维奈克拉联合5-阿扎胞苷交替方案治疗。复合完全缓解率达93%,84%患者可测量残留病阴性,中位随访22.1个月时中位总生存和无病生存均未达到。
要点
- 维奈克拉联合克拉屈滨/低剂量阿糖胞苷与5-阿扎胞苷交替方案在老年或不适合强化疗的新诊断AML中复合完全缓解率93%。
- 84%患者可测量残留病阴性,4周内死亡率2%,中位随访22.1个月时中位总生存和无病生存均未达到。
- 最常见3/4级非血液学不良事件为发热性中性粒细胞减少(33例)和肺炎(14例),1例发生4级肿瘤溶解综合征。
核心结论
- 维奈克拉联合克拉屈滨/低剂量阿糖胞苷与维奈克拉联合5-阿扎胞苷交替方案是老年或不适合强化疗的新诊断AML的有效方案,总生存和无病生存率令人鼓舞。
- 作者认为需要进一步研究该不含蒽环类骨架方案在年轻但不适合强化疗患者中的应用,并与标准一线治疗进行比较。
研究设计与样本
- 这是一项II期研究,研究维奈克拉联合克拉屈滨/低剂量阿糖胞苷与维奈克拉联合5-阿扎胞苷交替方案在老年(≥60岁)或不适合强化疗的新诊断AML患者中的疗效。
- 共治疗60例患者,中位年龄68岁(范围57-84岁)。
- 主要终点为复合完全缓解率(完全缓解加血液学未完全恢复的完全缓解);次要终点为总生存、无病生存、总缓解率和毒性。
主要发现
- 按欧洲白血病网危险分层,有利、中间和不良风险分别占23%、33%和43%。
- 60例可评估患者中56例有缓解,复合完全缓解率为93%,84%患者可测量残留病阴性。
- 4周内死亡1例(2%)。
- 中位随访22.1个月,中位总生存和无病生存均尚未达到。
- 最常见的3/4级非血液学不良事件为发热性中性粒细胞减少(33例)和肺炎(14例),1例患者发生4级肿瘤溶解综合征。
局限性
- 作者认为需要进一步研究该不含蒽环类骨架方案在年轻但不适合强化疗患者中的应用,并与标准一线治疗进行比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The combination of venetoclax and 5-azacitidine (5-AZA) for older or unfit patients with acute myeloid leukemia (AML) improves remission rates and survival compared with 5-AZA alone. We hypothesized that the addition of venetoclax to cladribine (CLAD)/low-dose araC (low-dose cytarabine [LDAC]) alternating with 5-AZA backbone may further improve outcomes for older patients with newly diagnosed AML. METHODS: This is a phase II study investigating the combination of venetoclax and CLAD/LDAC alternating with venetoclax and 5-AZA in older (≥ 60 years) or unfit patients with newly diagnosed AML. The primary objective was composite complete response (CR) rate (CR plus CR with incomplete blood count recovery); secondary end points were overall survival, disease-free survival (DFS), overall response rate, and toxicity. RESULTS: A total of 60 patients were treated; median age was 68 years (range, 57-84 years). By European LeukemiaNet, 23%, 33%, and 43% were favorable, intermediate, and adverse risk, respectively. Fifty-six of 60 evaluable patients responded (composite CR: 93%) and 84% were negative for measurable residual disease. There was one death (2%) within 4 weeks. With a median follow-up of 22.1 months, the median overall survival and DFS have not yet been reached. The most frequent grade 3/4 nonhematologic adverse events were febrile neutropenia (n = 33) and pneumonia (n = 14). One patient developed grade 4 tumor lysis syndrome. CONCLUSION: Venetoclax and CLAD/LDAC alternating with venetoclax and 5-AZA is an effective regimen among older or unfit patients with newly diagnosed AML. The rates of overall survival and DFS are encouraging. Further study of this non-anthracycline-containing backbone in younger patients, unfit for intensive chemotherapy, as well as comparisons to standard frontline therapies is warranted.
引用
- Kadia TM, Reville PK, Wang X, et al. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2022. PMID: 35704787. doi:10.1200/JCO.21.02823
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。